6-K
Radiopharm Theranostics Ltd (RADX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of July 2026
Commission File Number: 001-41621
RADIOPHARM THERANOSTICS LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South,Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
RADIOPHARM THERANOSTICS LIMITED
EXPLANATORY NOTE
Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on July 3, 2026 titled:
“Radiopharm Receives $5.9M R&D Tax Incentive”
A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.
This report on Form 6-K (including any exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any registration statement or prospectus under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such registration statement or prospectus.
1
EXHIBITS
| Exhibit <br><br>Number | Description |
|---|---|
| 99.1 | Radiopharm Receives $5.9M R&D Tax Incentive |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| RADIOPHARM THERANOSTICS LIMITED | ||
|---|---|---|
| Date: July 3, 2026 | By: | /s/ Nathan Jong |
| Nathan Jong | ||
| Company Secretary |
3
Exhibit 99.1
| ASX ANNOUNCEMENT 3 July 2026 |  |
|---|
RadiopharmReceives $5.9M R&D Tax Incentive
Sydney, Australia – 3 July 2026 – Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce it has received its research and development (R&D) tax refund for the 2025 financial year, totalling A$.5,885,131, including A$104,475 interest.
The refund is received as part of the Australian Government’s R&D tax incentive, which provides companies engaging in appropriate and eligible activities with a refundable tax offset of up to 43.5%.
The refund received by Radiopharm will provide important funding for continued development of its portfolio of radiopharmaceutical products for diagnostic and therapeutic applications.
AboutRadiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and five Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain. Learn more at radiopharmtheranostics.com.
Authorizedon behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.
Formore information:
Investors:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
Anne Marie Fields
Precision AQ (formerly Stern IR)
Paul Hopper
Executive Chairman
P: +61 406 671 515
RadiopharmTheranostics LimitedSuite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 AustraliaABN: 57 647 877 889
| ASX ANNOUNCEMENT 3 July 2026 | |
|---|
Media
Matt Wright
NWR Communications
P: +61 451 896 420
FollowRadiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
X – https://x.com/TeamRadiopharm
LinkedIn – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/
RadiopharmTheranostics LimitedSuite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 AustraliaABN: 57 647 877 889